Hospira Inc. Third Quarter Earnings on Deck

The Cheat Sheet

S&P 500 component Hospira, Inc. will unveil its latest earnings on Wednesday, October 26, 2011. Hospira is a global specialty pharmaceutical and medication delivery company that develops products that help improve the safety and productivity of patient care.

Hospira, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of 66 cents per share, a decline of 10.8% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.07. Between one and three months ago, the average estimate moved down. It also has dropped from 95 cents during the last month. For the year, analysts are projecting profit of $2.95 per share, a decline of 10.9% from last year.

Past Earnings Performance: The company is looking to beat analyst estimates for the third quarter in a row. Last quarter, it beat estimates with net income of 94 cents per share against the mean estimate of 78 cents. In the prior quarter, the company reported profit of 93 cents.

Investing Insights: Amazon.com has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: Analysts are projecting a rise of 9.6% in revenue from the year-earlier quarter to $1.04 billion.

Analyst Ratings: Analysts seem relatively indifferent about Hospira with eight of 12 analysts surveyed maintaining a hold rating.

A Look Back: In the second quarter, profit rose 72% to $143.6 million (85 cents a share) from $83.5 million (49 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 9.9% to $1.06 billion from $968.2 million.

Key Stats:

A year-over-year revenue increase in the second quarter snapped a streak of three consecutive quarters of revenue declines. Revenue fell 0.5% in the first quarter, 6% in the fourth quarter of the last fiscal year and 5.8% in the third quarter of the last fiscal year.

Competitors to Watch: Teva Pharmaceutical Industries Ltd , Mylan Inc. , Akorn, Inc. , Novartis AG , Baxter International Inc. , Watson Pharmaceuticals, Inc. , Pfizer Inc. , DURECT Corporation , ICU Medical, Incorporated , and Allergan, Inc. .

Stock Price Performance: During July 27, 2011 to October 20, 2011, the stock price had fallen $23.73 (-45.3%) from $52.40 to $28.67. It saw one of its worst periods between December 17, 2010 and December 29, 2010 when shares fell for eight-straight days, falling 3.4% (-$1.94) over that span. The stock price saw one of its best stretches over the last year between March 28, 2011 and April 5, 2011 when shares rose for seven-straight days, rising 4.7% (+$2.54) over that span. Shares are down $27.02 (-48.5%) year to date.

(Source: Xignite Financials)

Investing Insights: Amazon.com has a Stock Chart Technical Analysts Dream About.

 

View Comments (0)